Valbiotis R&D Center, Valbiotis, Perigny, France.
Laboratoire AME2P, Université Clermont Auvergne, Clermont-Ferrand, France.
Diabetes Obes Metab. 2022 Dec;24(12):2331-2340. doi: 10.1111/dom.14817. Epub 2022 Aug 1.
The plant-based polyphenol-rich extract TOTUM-63 improves glucose homeostasis in various preclinical models of obesity and type 2 diabetes (T2D). A pilot exploratory study showed that TOTUM-63 has good safety and tolerability profiles, and beneficial effects on postprandial glucose control in healthy individuals with overweight. The aim of this study was to assess the effects of TOTUM-63 on glycaemic control in individuals with prediabetes or early stage newly-diagnosed T2D (which does not require pharmacological treatment).
This study was a multicentre, randomized, double-blind, placebo-controlled trial. Individuals with prediabetes or early stage newly-diagnosed T2D and with overweight/abdominal obesity received TOTUM-63 (5 g/day) or placebo for 6 months. The primary outcome was the change in fasting blood glucose.
Fifty-one participants (age: 57.1 ± 10 years; body mass index: 31.3 ± 5.7 kg.m ; 35 women and 16 men) completed the study (n = 38 TOTUM-63, n = 13 placebo). After 6 months, blood glucose concentration after fasting and after the 2-h oral glucose tolerance test was reduced in the TOTUM-63-treated group compared with the placebo group (placebo-corrected difference between baseline and month 6: -0.71 mmol/L, p < .05, and -1.93 mmol/L, p < .05, respectively). TOTUM-63 was safe and well tolerated and significantly reduced body weight gain (-1.9 kg; p < .05), waist circumference (-4.5 cm; p < .001), circulating triglycerides (-0.54 mmol/L; p < .01) and low-density lipoprotein-cholesterol (-0.38 mmol/L; p < .05) compared with placebo.
TOTUM-63 lowered fasting blood glucose in participants with impaired fasting glycaemia and glucose intolerance. Moreover, TOTUM-63 showed a good safety and tolerability profile and improved several metabolic syndrome features. Therefore, TOTUM-63 is a promising candidate for T2D prevention.
富含植物多酚的提取物 TOTUM-63 可改善肥胖和 2 型糖尿病(T2D)多种临床前模型中的葡萄糖稳态。一项初步探索性研究表明,TOTUM-63 具有良好的安全性和耐受性,并且可改善超重的健康个体的餐后血糖控制。本研究旨在评估 TOTUM-63 对空腹血糖受损或早期新诊断的 T2D(无需药物治疗)患者血糖控制的影响。
这是一项多中心、随机、双盲、安慰剂对照试验。空腹血糖受损或早期新诊断的 T2D 且超重/腹型肥胖的患者接受 TOTUM-63(5g/天)或安慰剂治疗 6 个月。主要结局是空腹血糖的变化。
51 名参与者(年龄:57.1±10 岁;体重指数:31.3±5.7kg/m;35 名女性和 16 名男性)完成了研究(n=38 例 TOTUM-63,n=13 例安慰剂)。治疗 6 个月后,与安慰剂组相比,TOTUM-63 治疗组的空腹和 2 小时口服葡萄糖耐量试验后的血糖浓度降低(安慰剂校正的基线至 6 个月差异:-0.71mmol/L,p<0.05 和-1.93mmol/L,p<0.05)。TOTUM-63 安全且耐受良好,可显著降低体重增加(-1.9kg;p<0.05)、腰围(-4.5cm;p<0.001)、循环甘油三酯(-0.54mmol/L;p<0.01)和低密度脂蛋白胆固醇(-0.38mmol/L;p<0.05)与安慰剂相比。
TOTUM-63 可降低空腹血糖受损和葡萄糖耐量受损患者的空腹血糖。此外,TOTUM-63 显示出良好的安全性和耐受性,并改善了多种代谢综合征特征。因此,TOTUM-63 是预防 T2D 的有希望的候选药物。